Second and third TNF inhibitors in European patients with axial spondyloarthritis: Effectiveness and impact of the reason for switching.
Louise LindeLykke Midtbøll ØrnbjergCecilie Heegaard BraheJohan Karlsson WallmanDaniela Di GiuseppeJakub ZávadaIsabel CastrejonFederico Díaz-GonzalezZiga RotarMatija TomšičBente GlintborgBjorn GudbjornssonArni Jon GeirssonBrigitte MichelsenEirik Klami KristianslundMaria José SantosAnabela BarcelosDan NordströmKari K EklundAdrian CiureaMichael NissenServet AkarLise Hejl HyldstrupNiels Steen KroghMerete Lund HetlandMikkel ØstergaardPublished in: Rheumatology (Oxford, England) (2023)
A similar proportion of axSpA patients remained on a second and third TNFi after one year, but with low remission rates for the third TNFi. Remission rates on the second TNFi (but not the third) were higher if the withdrawal reason from the preceding TNFi was AE versus LOE.